JP5404402B2 - 医薬適用のための乾燥した再構成したベシクル形成 - Google Patents

医薬適用のための乾燥した再構成したベシクル形成 Download PDF

Info

Publication number
JP5404402B2
JP5404402B2 JP2009530810A JP2009530810A JP5404402B2 JP 5404402 B2 JP5404402 B2 JP 5404402B2 JP 2009530810 A JP2009530810 A JP 2009530810A JP 2009530810 A JP2009530810 A JP 2009530810A JP 5404402 B2 JP5404402 B2 JP 5404402B2
Authority
JP
Japan
Prior art keywords
lipid
liposome
anion
liposomes
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009530810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505785A5 (enExample
JP2010505785A (ja
Inventor
ヘラーブラント クラウス
シュッツ アンドレアス
ジークル ライナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Scil Technology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology GmbH filed Critical Scil Technology GmbH
Publication of JP2010505785A publication Critical patent/JP2010505785A/ja
Publication of JP2010505785A5 publication Critical patent/JP2010505785A5/ja
Application granted granted Critical
Publication of JP5404402B2 publication Critical patent/JP5404402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009530810A 2006-10-06 2007-10-05 医薬適用のための乾燥した再構成したベシクル形成 Expired - Fee Related JP5404402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06021093 2006-10-06
EP06021093.7 2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en) 2006-10-06 2007-10-05 Dried reconstituted vesicle formation for pharmaceutical application

Publications (3)

Publication Number Publication Date
JP2010505785A JP2010505785A (ja) 2010-02-25
JP2010505785A5 JP2010505785A5 (enExample) 2013-06-20
JP5404402B2 true JP5404402B2 (ja) 2014-01-29

Family

ID=38910893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009530810A Expired - Fee Related JP5404402B2 (ja) 2006-10-06 2007-10-05 医薬適用のための乾燥した再構成したベシクル形成
JP2009530811A Expired - Fee Related JP5484059B2 (ja) 2006-10-06 2007-10-05 脊髄核インプラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009530811A Expired - Fee Related JP5484059B2 (ja) 2006-10-06 2007-10-05 脊髄核インプラント

Country Status (17)

Country Link
US (3) US9526761B2 (enExample)
EP (2) EP2081551B1 (enExample)
JP (2) JP5404402B2 (enExample)
KR (1) KR101333279B1 (enExample)
CN (3) CN101528197B (enExample)
CA (1) CA2664637C (enExample)
CY (1) CY1113934T1 (enExample)
DK (1) DK2081551T3 (enExample)
ES (2) ES2400162T3 (enExample)
HR (1) HRP20130328T1 (enExample)
PL (1) PL2081551T3 (enExample)
PT (1) PT2081551E (enExample)
RS (1) RS52706B (enExample)
RU (1) RU2443412C2 (enExample)
SI (1) SI2081551T1 (enExample)
TW (1) TWI455731B (enExample)
WO (2) WO2008040557A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
EP1868539A2 (en) 2005-04-15 2007-12-26 Musculoskeletal Transplant Foundation Vertebral disc repair
US7959683B2 (en) 2006-07-25 2011-06-14 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
CA2737374C (en) 2008-09-26 2017-03-28 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
WO2011103462A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
US10390877B2 (en) 2011-12-30 2019-08-27 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
IL238516B (en) 2012-11-05 2022-08-01 Relievant Medsystems Inc System and methods for creating curved pathways through bone and regulating the nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
ES2726924T3 (es) * 2014-12-18 2019-10-10 Bracco Suisse Sa Formulación de microvesículas dirigidas rellenas de gas
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
WO2017046314A2 (en) * 2015-09-18 2017-03-23 Sanofi Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
CN110582282A (zh) * 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
TWI806894B (zh) * 2017-08-28 2023-07-01 台灣微脂體股份有限公司 緩釋麻醉劑組成物及其製備方法
US11389405B2 (en) 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
DK3864163T3 (da) * 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
AU2020346827B2 (en) 2019-09-12 2026-03-12 Relievant Medsystems, Inc. Systems and methods for tissue modulation
AU2021306313B2 (en) 2020-07-10 2026-07-09 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
AU2021409967A1 (en) 2020-12-22 2023-08-03 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用
CN221431621U (zh) * 2023-07-10 2024-07-30 常州富谦生物科技有限公司 一种多层膜结构

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (enExample) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
AU8329391A (en) * 1990-08-08 1992-03-02 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DK1244388T3 (da) * 1999-12-06 2007-05-14 Warsaw Orthopedic Inc Indretning til behandling af mellemhvirvelskiver
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
WO2005113032A2 (en) * 2004-05-21 2005-12-01 Synthes (U.S.A.) Replacement of nucleus pulposus using a hydrogel
CA2567405A1 (en) * 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Also Published As

Publication number Publication date
WO2008040556A1 (en) 2008-04-10
EP2081551A1 (en) 2009-07-29
US20160220638A1 (en) 2016-08-04
TW200829283A (en) 2008-07-16
DK2081551T3 (da) 2013-05-06
RU2443412C2 (ru) 2012-02-27
SI2081551T1 (sl) 2013-05-31
US20090285880A1 (en) 2009-11-19
US9526761B2 (en) 2016-12-27
JP2010505482A (ja) 2010-02-25
KR20090086397A (ko) 2009-08-12
JP5484059B2 (ja) 2014-05-07
PT2081551E (pt) 2013-02-18
RS52706B (sr) 2013-08-30
HRP20130328T1 (hr) 2013-05-31
JP2010505785A (ja) 2010-02-25
EP2081551B1 (en) 2013-01-23
CA2664637A1 (en) 2008-04-10
CY1113934T1 (el) 2016-07-27
TWI455731B (zh) 2014-10-11
ES2708851T3 (es) 2019-04-11
ES2400162T3 (es) 2013-04-08
KR101333279B1 (ko) 2013-11-27
EP2086507B1 (en) 2018-11-07
RU2009117170A (ru) 2010-11-20
CN101605534A (zh) 2009-12-16
EP2086507A1 (en) 2009-08-12
CN101528197A (zh) 2009-09-09
WO2008040557A1 (en) 2008-04-10
US20090297580A1 (en) 2009-12-03
CN101528197B (zh) 2013-02-13
PL2081551T3 (pl) 2013-06-28
CA2664637C (en) 2013-11-12
CN102940878A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
KR101333279B1 (ko) 약학적 응용을 위한 건조된 재구성 소포 형성
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
US20070166368A1 (en) Protein-Stabilized Liposomal Formulations of Pharmaceutical Agents
US5977172A (en) PGE1 -containing-freeze dried preparation and process for the production thereof
EP0514506B1 (en) Lipid formulation system
WO1995016464A1 (en) Controlled release of pharmaceutically active substances for immunotherapy
KR20080055712A (ko) 단백질 안정화 제형
JPH08511245A (ja) 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体
JP2014521636A (ja) ペプチドおよびポリペプチド分子の制御放出のためのマトリクス組成物
US20120100067A1 (en) Solubilisation Method
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2018535952A (ja) 医薬用コロイド粒子
KR20080044845A (ko) 철 킬레이트제를 포함하는 약학적 조성물
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
JPWO2003015753A1 (ja) リポソーム製剤
CN114302709A (zh) 包裹腺苷的脂质体
JP2006273812A (ja) リポソーム製剤の製造方法
JPS61501686A (ja) リポソ−ム↓−ゲル組成物
JP2006280376A (ja) 細胞への遺伝子導入用組成物
WO1991007962A1 (fr) Emulsion de graisse
HK1240506A1 (en) Targeted gas-filled microvesicles formulation
HK1240506B (en) Targeted gas-filled microvesicles formulation
KR20050020988A (ko) 스텔스 지질 나노캡슐, 이의 제조 방법, 및 유효성분(들)을 위한 담체로서 이의 용도
HK1021622B (en) Preparation for the transport of an active substance across barriers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100811

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130131

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131029

R150 Certificate of patent or registration of utility model

Ref document number: 5404402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees